Baxter International Inc (BAX) Position Raised by Mn Services Vermogensbeheer B.V.

Mn Services Vermogensbeheer B.V. increased its holdings in shares of Baxter International Inc (NYSE:BAX) by 0.9% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 86,905 shares of the medical instruments supplier’s stock after purchasing an additional 800 shares during the quarter. Mn Services Vermogensbeheer B.V.’s holdings in Baxter International were worth $7,066,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of BAX. Vanguard Group Inc lifted its stake in Baxter International by 1.3% during the third quarter. Vanguard Group Inc now owns 36,398,931 shares of the medical instruments supplier’s stock worth $2,805,993,000 after purchasing an additional 470,198 shares during the last quarter. Cozad Asset Management Inc. lifted its stake in Baxter International by 6.2% in the fourth quarter. Cozad Asset Management Inc. now owns 3,423 shares of the medical instruments supplier’s stock valued at $225,000 after buying an additional 200 shares during the last quarter. CX Institutional lifted its stake in Baxter International by 705.2% in the fourth quarter. CX Institutional now owns 781 shares of the medical instruments supplier’s stock valued at $51,000 after buying an additional 684 shares during the last quarter. Gofen & Glossberg LLC IL lifted its stake in Baxter International by 6.9% in the fourth quarter. Gofen & Glossberg LLC IL now owns 15,493 shares of the medical instruments supplier’s stock valued at $1,020,000 after buying an additional 1,004 shares during the last quarter. Finally, Stock Yards Bank & Trust Co. lifted its stake in Baxter International by 5.1% in the fourth quarter. Stock Yards Bank & Trust Co. now owns 6,744 shares of the medical instruments supplier’s stock valued at $444,000 after buying an additional 328 shares during the last quarter. Hedge funds and other institutional investors own 86.12% of the company’s stock.

In related news, Director Peter S. Hellman sold 5,680 shares of the company’s stock in a transaction on Monday, April 1st. The stock was sold at an average price of $81.89, for a total transaction of $465,135.20. Following the transaction, the director now owns 28,774 shares of the company’s stock, valued at $2,356,302.86. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Thomas T. Stallkamp sold 1,000 shares of the company’s stock in a transaction on Friday, March 1st. The stock was sold at an average price of $75.16, for a total value of $75,160.00. Following the transaction, the director now directly owns 6,780 shares in the company, valued at approximately $509,584.80. The disclosure for this sale can be found here. In the last three months, insiders sold 57,187 shares of company stock worth $4,447,619. Corporate insiders own 0.70% of the company’s stock.

A number of equities research analysts have weighed in on BAX shares. Zacks Investment Research cut Baxter International from a “hold” rating to a “sell” rating in a research note on Wednesday, January 23rd. Piper Jaffray Companies reiterated an “overweight” rating and issued a $80.00 price objective on shares of Baxter International in a research note on Friday, February 1st. Barclays upgraded Baxter International from an “underweight” rating to an “equal weight” rating and boosted their price objective for the company from $67.00 to $72.00 in a research note on Friday, February 1st. Morgan Stanley boosted their price objective on Baxter International from $80.00 to $83.00 and gave the company an “overweight” rating in a research note on Tuesday, March 5th. Finally, Wells Fargo & Co boosted their price objective on Baxter International from $80.00 to $89.00 and gave the company an “outperform” rating in a research note on Wednesday, April 3rd. Four equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. Baxter International has an average rating of “Buy” and an average target price of $78.69.

NYSE:BAX opened at $75.88 on Thursday. The company has a market capitalization of $38.49 billion, a PE ratio of 24.88, a P/E/G ratio of 1.78 and a beta of 0.96. The company has a current ratio of 1.83, a quick ratio of 1.30 and a debt-to-equity ratio of 0.50. Baxter International Inc has a 12-month low of $61.05 and a 12-month high of $82.25.

Baxter International (NYSE:BAX) last released its earnings results on Thursday, April 25th. The medical instruments supplier reported $0.76 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.68 by $0.08. The business had revenue of $2.63 billion for the quarter, compared to analyst estimates of $2.61 billion. Baxter International had a return on equity of 20.04% and a net margin of 14.27%. The company’s revenue for the quarter was down 1.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.70 earnings per share. Equities analysts predict that Baxter International Inc will post 3.32 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Monday, July 1st. Stockholders of record on Friday, June 7th will be issued a $0.22 dividend. The ex-dividend date of this dividend is Thursday, June 6th. This represents a $0.88 dividend on an annualized basis and a dividend yield of 1.16%. This is a positive change from Baxter International’s previous quarterly dividend of $0.19. Baxter International’s payout ratio is presently 24.92%.

WARNING: “Baxter International Inc (BAX) Position Raised by Mn Services Vermogensbeheer B.V.” was first reported by The Lincolnian Online and is the property of of The Lincolnian Online. If you are accessing this piece on another site, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The original version of this piece can be read at https://www.thelincolnianonline.com/2019/05/16/baxter-international-inc-bax-position-raised-by-mn-services-vermogensbeheer-b-v.html.

Baxter International Profile

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.

Recommended Story: What is an Initial Public Offering (IPO)?

Want to see what other hedge funds are holding BAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Baxter International Inc (NYSE:BAX).

Institutional Ownership by Quarter for Baxter International (NYSE:BAX)

Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.